Recruiting

OCT Devices

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07449195

Conditions

Ocular Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Intalight Dream OCT

Heidelberg Spectralis OCT

Study Details

Brief summary:

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Conditions

Ocular Tumor

Study ID

NCT07449195

Start date

Feb 27, 2026

Status verified date

May, 2026

Completion date

Feb 27, 2028

Anticipated

Primary completion date

Feb 27, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥18 years.
  • At least 1 eye that has an intraocular or ocular surface tumor.
  • The presence of a natural crystalline lens or intraocular lens.
  • Pupils that can dilate up to at least 3 mm in the study eyes.
  • The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging.
  • Patients must be able to fixate on the imaging target.
  • Patients must be able to sit still for a period of time (approximately 2 minutes).

Exclusion Criteria:

  • Does not meet ALL of the above conditions

Study Design

Enrollment

60 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Participants with Ocular Tumor

Participants will have at least 1 eye that has an intraocular or ocular surface tumor.

Interventions

Intalight Dream OCT

This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.

Heidelberg Spectralis OCT

This is the standard of care for optical imaging.

Primary outcome measure

  • Image quality for participants [ Time Frame: Up to 1 year ]
  • Field of view for participants [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Jasmine Francis, MD

212-639-7266francij1@mskcc.org

David Abramson, MD

212-639-7232abramsod@mskcc.org

Locations

Memorial Sloan Kettering at Basking Ridge (Consent Only)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Monmouth (Consent only)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Bergen (Consent Only)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)

Recruiting

Commack, New York, United States, 11725

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Westchester (Consent Only)

Recruiting

Harrison, New York, United States, 10604

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

Recruiting

New York, New York, United States, 10065

Contacts

Jasmine Francis, MD

212-639-7266

Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Jasmine Francis, MD

212-639-7266

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

May 13, 2026

Last verified

May, 2026

Keywords

  • Ocular Tumors
  • 25-314
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-05-13.